ExLibris header image
SFX Logo
Title: Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development
Source:

Blood [0006-4971] Schaffner, Florence yr:2010


Collapse list of basic services Basic
Sorry, no full text available...
Please use the document delivery service (see below)  
Holding information
Holdings in library search engine ALBERT GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Aghourian, M N. "In vivo monitoring of venous thrombosis in mice." Journal of thrombosis and haemostasis 10.3 (2012): 447-452. Link to Full Text for this item Link to SFX for this item
2. Petersen, Lars C. "Microarray studies of factor VIIa-activated cancer cells." Thrombosis Research 122 Suppl 1 (2008): -3. Link to SFX for this item
3. Denoyelle, C. "Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study." Carcinogenesis 22.8 (2001): 1139-48. Link to SFX for this item
4. Castellino, Francis A. "Factor VII deficiency impairs cutaneous wound healing in mice." Molecular medicine 16.5 (2010): 167-176. Link to Full Text for this item Link to SFX for this item
5. Follenzi, S. "Role of bone marrow transplantation for correcting hemophilia A in mice." Blood 119.23 (2012): 5532-5542. Link to SFX for this item
6. Myerson, J. "Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis." Journal of thrombosis and haemostasis 9.7 (2011): 1292-1300. Link to Full Text for this item Link to SFX for this item
7. Petersen, G M C. "Transcriptional program induced by factor VIIa-tissue factor, PAR1 and PAR2 in MDA-MB-231 cells." Journal of thrombosis and haemostasis 5.8 (2007): 1588-97. Link to Full Text for this item Link to SFX for this item
8. Kaiser, B. "Pharmacology of Synthetic Thrombin Inhibitors of the Tripeptide Type." Cardiovascular drug reviews 10.1 (1992): 71-87. Link to Full Text for this item Link to SFX for this item
9. Mousa, S A. "Novel technetium-99m-labeled platelet GPIIb/IIIa receptor antagonists as potential imaging agents for venous and arterial thrombosis." Coronary artery disease (1998): 131-141. Link to SFX for this item
10. Dodds, W J. "Hepatic influence on splenic synthesis and release of coagulation activities." Science 166.3907 (1969): 882-883. Link to SFX for this item
11. Kuliopulos, A. "Matrix Metalloproteases and PAR Activation." Blood 2011. 1817-1818. Link to SFX for this item
12. Tsakiris, D A A. "Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease." Atherosclerosis 142.1 (1999): 193-200. Link to Full Text for this item Link to SFX for this item
13. Bruns, Christiane J J. "Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF." Blood 105.11 (2005): 4463-9. Link to SFX for this item
14. Marutsuka, K. "Protease-activated receptor 2 (PAR2) mediates vascular smooth muscle cell migration induced by tissue factor/factor VIIa complex." Thrombosis Research 107.5 (2002): 271-6. Link to Full Text for this item Link to SFX for this item
15. Ahamed, J. "Protease-activated receptor 2-dependent phosphorylation of the tissue factor cytoplasmic domain." The Journal of biological chemistry 279.22: 23038-23044. Link to SFX for this item
16. BAJAJ, S P P. "Fibronectin-adherent monocytes express tissue factor and tissue factor pathway inhibitor whereas endotoxin-stimulated monocytes primarily express tissue factor: physiologic and pathologic implications." Journal of thrombosis and haemostasis 5.7 (2007): 1493-1499. Link to Full Text for this item Link to SFX for this item
View More...
View Less...
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.